BofA/Merrill Lynch Downgrades Dr. Reddy's Laboratories (RDY) to Neutral
Tweet
Share
E-mailGet Alerts RDY Hot Sheet
Price: $12.22 +0.91%
Rating Summary:
8 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 33 | Down: 45 | New: 4
Rating Summary:
8 Buy, 2 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 33 | Down: 45 | New: 4
Join SI Premium – FREE
BofA/Merrill Lynch downgraded Dr. Reddy's Laboratories (NYSE: RDY) from Buy to Neutral following Q3 results.
For an analyst ratings summary and ratings history on Dr. Reddy's Laboratories click here. For more ratings news on Dr. Reddy's Laboratories click here.
Shares of Dr. Reddy's Laboratories closed at $34.82 yesterday.
For an analyst ratings summary and ratings history on Dr. Reddy's Laboratories click here. For more ratings news on Dr. Reddy's Laboratories click here.
Shares of Dr. Reddy's Laboratories closed at $34.82 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Atlassian results seen as 'game changer' for AI kills software worries
- Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United State
- Cannonball Research Downgrades The Trade Desk (TTD) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
